Logo image of ENTX

ENTERA BIO LTD (ENTX) Stock Fundamental Analysis

NASDAQ:ENTX - Nasdaq - IL0011429839 - Common Stock - Currency: USD

2.36  +0.13 (+5.83%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ENTX. ENTX was compared to 566 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ENTX as it has an excellent financial health rating, but there are worries on the profitability. ENTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ENTX had negative earnings in the past year.
ENTX had a negative operating cash flow in the past year.
In the past 5 years ENTX always reported negative net income.
ENTX had a negative operating cash flow in each of the past 5 years.
ENTX Yearly Net Income VS EBIT VS OCF VS FCFENTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of ENTX (-101.61%) is worse than 77.03% of its industry peers.
ENTX's Return On Equity of -118.08% is in line compared to the rest of the industry. ENTX outperforms 40.99% of its industry peers.
Industry RankSector Rank
ROA -101.61%
ROE -118.08%
ROIC N/A
ROA(3y)-92.24%
ROA(5y)-87.81%
ROE(3y)-104.97%
ROE(5y)-103.66%
ROIC(3y)N/A
ROIC(5y)N/A
ENTX Yearly ROA, ROE, ROICENTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 4.97%, ENTX is in the better half of the industry, outperforming 71.91% of the companies in the same industry.
ENTX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ENTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-47.86%
GM growth 5Y-16.84%
ENTX Yearly Profit, Operating, Gross MarginsENTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

ENTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ENTX has more shares outstanding
The number of shares outstanding for ENTX has been increased compared to 5 years ago.
ENTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ENTX Yearly Shares OutstandingENTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ENTX Yearly Total Debt VS Total AssetsENTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

An Altman-Z score of 27.05 indicates that ENTX is not in any danger for bankruptcy at the moment.
The Altman-Z score of ENTX (27.05) is better than 96.29% of its industry peers.
There is no outstanding debt for ENTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 27.05
ROIC/WACCN/A
WACC9.03%
ENTX Yearly LT Debt VS Equity VS FCFENTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 7.63 indicates that ENTX has no problem at all paying its short term obligations.
The Current ratio of ENTX (7.63) is better than 72.79% of its industry peers.
ENTX has a Quick Ratio of 7.63. This indicates that ENTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.63, ENTX is in the better half of the industry, outperforming 73.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.63
Quick Ratio 7.63
ENTX Yearly Current Assets VS Current LiabilitesENTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

ENTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.35%, which is quite good.
The Revenue has been decreasing by -5.49% on average over the past years.
EPS 1Y (TTM)19.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-31.78%
Revenue growth 5Y-5.49%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-124.4%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENTX Yearly Revenue VS EstimatesENTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2024 0 200K 400K
ENTX Yearly EPS VS EstimatesENTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENTX. In the last year negative earnings were reported.
Also next year ENTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTX Price Earnings VS Forward Price EarningsENTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTX Per share dataENTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ENTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTERA BIO LTD

NASDAQ:ENTX (5/2/2025, 8:00:01 PM)

2.36

+0.13 (+5.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/amc
Earnings (Next)05-09 2025-05-09/amc
Inst Owners26.78%
Inst Owner Change0%
Ins Owners2.69%
Ins Owner Change0.9%
Market Cap107.19M
Analysts82.86
Price Target10.2 (332.2%)
Short Float %0.21%
Short Ratio1.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.2%
Min EPS beat(2)-56.86%
Max EPS beat(2)26.47%
EPS beat(4)3
Avg EPS beat(4)-2.53%
Min EPS beat(4)-56.86%
Max EPS beat(4)26.47%
EPS beat(8)6
Avg EPS beat(8)4.94%
EPS beat(12)10
Avg EPS beat(12)11.24%
EPS beat(16)13
Avg EPS beat(16)6.78%
Revenue beat(2)2
Avg Revenue beat(2)51.96%
Min Revenue beat(2)2.94%
Max Revenue beat(2)100.98%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 592.22
P/FCF N/A
P/OCF N/A
P/B 13.27
P/tB 13.27
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -101.61%
ROE -118.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.97%
FCFM N/A
ROA(3y)-92.24%
ROA(5y)-87.81%
ROE(3y)-104.97%
ROE(5y)-103.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-47.86%
GM growth 5Y-16.84%
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.52%
Cap/Sales 1.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.63
Quick Ratio 7.63
Altman-Z 27.05
F-Score3
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)40.07%
Cap/Depr(5y)48.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y-124.4%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-31.78%
Revenue growth 5Y-5.49%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.73%
OCF growth 3YN/A
OCF growth 5YN/A